Literature DB >> 25783884

Screening for small molecule disruptors of AKAP-PKA interactions.

Carolin Schächterle1, Frank Christian, João Miguel Parente Fernandes, Enno Klussmann.   

Abstract

Protein-protein interactions (PPIs) are highly specific and diverse. Their selective inhibition with peptides, peptidomimetics, or small molecules allows determination of functions of individual PPIs. Moreover, inhibition of disease-associated PPIs may lead to new concepts for the treatment of diseases with an unmet medical need. Protein kinase A (PKA) is an ubiquitously expressed protein kinase that controls a plethora of cellular functions. A-kinase anchoring proteins (AKAPs) are multivalent scaffolding proteins that directly interact with PKA. AKAPs spatially and temporally restrict PKA activity to defined cellular compartments and thereby contribute to the specificity of PKA signaling. However, it is largely unknown which of the plethora of PKA-dependent signaling events involve interactions of PKA with AKAPs. Moreover, AKAP-PKA interactions appear to play a role in a variety of cardiovascular, neuronal, and inflammatory diseases, but it is unclear whether these interactions are suitable drug targets. Here we describe an enzyme-linked immunosorbent assay (ELISA) for the screening of small molecule libraries for inhibitors of AKAP-PKA interactions. In addition, we describe a homogenous time-resolved fluorescence (HTRF) assay for use in secondary validation screens. Small molecule inhibitors are invaluable molecular tools for elucidating the functions of AKAP-PKA interactions and may eventually lead to new concepts for the treatment of diseases where AKAP-PKA interactions represent potential drug targets.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25783884     DOI: 10.1007/978-1-4939-2537-7_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Determination of protein kinase A activity and inhibition by using hydroxyapatite nanoparticles as a fluorescent probe.

Authors:  Kaina Zhang; Ke Zeng; Congcong Shen; Shiyu Tian; Minghui Yang
Journal:  Mikrochim Acta       Date:  2018-03-16       Impact factor: 5.833

2.  Disruptors of AKAP-Dependent Protein-Protein Interactions.

Authors:  Ryan Walker-Gray; Tamara Pallien; Duncan C Miller; Andreas Oder; Martin Neuenschwander; Jens Peter von Kries; Sebastian Diecke; Enno Klussmann
Journal:  Methods Mol Biol       Date:  2022

3.  Hit-Validation Methodologies for Ligands Isolated from DNA-Encoded Chemical Libraries.

Authors:  Gunther Zimmermann; Yizhou Li; Ulrike Rieder; Martin Mattarella; Dario Neri; Jörg Scheuermann
Journal:  Chembiochem       Date:  2017-01-30       Impact factor: 3.164

Review 4.  The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular Diseases.

Authors:  Tanja Vukićević; Maike Schulz; Dörte Faust; Enno Klussmann
Journal:  Front Pharmacol       Date:  2016-02-11       Impact factor: 5.810

5.  Discovery of small molecule inhibitors that effectively disrupt IQGAP1-Cdc42 interaction in breast cancer cells.

Authors:  Samar Sayedyahossein; Jessica Smith; Elena Barnaeva; Zhigang Li; Jun Choe; Michael Ronzetti; Christopher Dextras; Xin Hu; Juan Marugan; Noel Southall; Bolormaa Baljinnyam; Louise Thines; Andy D Tran; Marc Ferrer; David B Sacks
Journal:  Sci Rep       Date:  2022-10-17       Impact factor: 4.996

Review 6.  Therapeutic strategies for anchored kinases and phosphatases: exploiting short linear motifs and intrinsic disorder.

Authors:  Patrick J Nygren; John D Scott
Journal:  Front Pharmacol       Date:  2015-07-28       Impact factor: 5.810

Review 7.  Targeting protein-protein interactions in complexes organized by A kinase anchoring proteins.

Authors:  Ana I Calejo; Kjetil Taskén
Journal:  Front Pharmacol       Date:  2015-09-08       Impact factor: 5.810

Review 8.  Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units.

Authors:  Vanessa L Wehbi; Kjetil Taskén
Journal:  Front Immunol       Date:  2016-06-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.